<?xml version='1.0' encoding='utf-8'?>
<document id="10516934"><sentence text="Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues." /><sentence text="This report investigates the quality and quantity of drug-drug interaction studies in recent new drug applications (NDAs)" /><sentence text=" Eighty-nine studies contained in 14 NDAs submitted between December 1995 and November 1996 to the U" /><sentence text="S" /><sentence text=" Food and Drug Administration (FDA) were reviewed" /><sentence text=" The results indicated that the median number of clinical drug-drug interaction studies per NDA was 6, almost double that of a 1994-1995 survey" /><sentence text=" In vitro metabolism data were present in 70% of the submissions" /><sentence text=" More than 50% of the submissions contained interaction studies using a battery of drugs (cimetidine, digoxin, or warfarin) without optimal use of the in vitro metabolism or in vivo mass balance data"><entity charOffset="90-100" id="DDI-PubMed.10516934.s8.e0" text="cimetidine" /><entity charOffset="102-109" id="DDI-PubMed.10516934.s8.e1" text="digoxin" /><entity charOffset="114-122" id="DDI-PubMed.10516934.s8.e2" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.10516934.s8.e0" e2="DDI-PubMed.10516934.s8.e0" /><pair ddi="false" e1="DDI-PubMed.10516934.s8.e0" e2="DDI-PubMed.10516934.s8.e1" /><pair ddi="false" e1="DDI-PubMed.10516934.s8.e0" e2="DDI-PubMed.10516934.s8.e2" /><pair ddi="false" e1="DDI-PubMed.10516934.s8.e1" e2="DDI-PubMed.10516934.s8.e1" /><pair ddi="false" e1="DDI-PubMed.10516934.s8.e1" e2="DDI-PubMed.10516934.s8.e2" /></sentence><sentence text=" Various study designs using a median number of 12 subjects were employed in the evaluation of drug-drug interactions" /><sentence text=" Some of the important study design factors such as dose size, dosing regimen, dosing duration, and timing of coadministration were considered, although not consistently, by the sponsors in their study design" /><sentence text=" Seventy-five percent of the studies used normal, healthy male subjects, and 25% used patients for whom the new molecular entities were intended" /><sentence text=" In 33% of the studies, female subjects were also recruited" /><sentence text=" Although the majority (80%) of the submissions still used p-values to determine the significance of drug interactions, 30% used a more relevant equivalence approach with 90% confidence intervals for key pharmacokinetic and/or pharmacodynamic parameter ratios to assess the extent of drug interactions" /><sentence text=" Overall, 82% of the studies concluded no interaction" /><sentence text=" Although population pharmacokinetic analysis can be a useful tool in studying drug-drug interactions, only 21% of the submissions used this approach" /><sentence text=" In summary, this assessment reveals that the quantity and quality of drug-drug interaction studies in NDAs have improved over the years" /><sentence text=" These improvements, as well as others that can be implemented, should result in more informative labeling and better patient care" /><sentence text=" FDA guidance for industry dealing with the design, analysis, and labeling language of in vivo metabolic drug-drug interactions has been developed to assist sponsors and FDA reviewers with these issues" /><sentence text="" /></document>